home / stock / obsv / obsv quote
Last: | $0.1018 |
---|---|
Change Percent: | -2.49% |
Open: | $0.1235 |
Close: | $0.1018 |
High: | $0.1235 |
Low: | $0.1 |
Volume: | 7,436,379 |
Last Trade Date Time: | 03/22/2023 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.1018 | $0.1235 | $0.1018 | $0.1235 | $0.1 | 7,436,379 | 03-22-2023 |
$0.1205 | $0.121 | $0.1205 | $0.127 | $0.1127 | 3,725,730 | 03-21-2023 |
$0.1185 | $0.1154 | $0.1185 | $0.1299 | $0.1154 | 2,846,402 | 03-20-2023 |
$0.1239 | $0.1183 | $0.1239 | $0.1347 | $0.1122 | 4,420,581 | 03-17-2023 |
$0.1198 | $0.1277 | $0.1198 | $0.13 | $0.114 | 4,170,714 | 03-16-2023 |
$0.1299 | $0.1284 | $0.1299 | $0.1343 | $0.1213 | 7,748,701 | 03-15-2023 |
$0.1288 | $0.1362 | $0.1288 | $0.1368 | $0.1255 | 2,807,920 | 03-14-2023 |
$0.1296 | $0.1355 | $0.1296 | $0.1397 | $0.1267 | 6,233,427 | 03-13-2023 |
$0.129 | $0.1511 | $0.129 | $0.1569 | $0.12 | 7,965,679 | 03-10-2023 |
$0.1508 | $0.1666 | $0.1508 | $0.17 | $0.15 | 9,970,006 | 03-09-2023 |
$0.179 | $0.1602 | $0.179 | $0.22 | $0.1589 | 59,612,998 | 03-08-2023 |
$0.14 | $0.167 | $0.14 | $0.179 | $0.12 | 15,461,929 | 03-07-2023 |
$0.1998 | $0.2232 | $0.1998 | $0.233 | $0.19 | 19,354,354 | 03-06-2023 |
$0.23 | $0.2089 | $0.23 | $0.2865 | $0.1764 | 197,590,054 | 03-03-2023 |
$0.106 | $0.1151 | $0.106 | $0.117 | $0.1 | 23,876,932 | 03-02-2023 |
$0.121 | $0.1222 | $0.121 | $0.13 | $0.1133 | 9,097,273 | 03-01-2023 |
$0.138 | $0.1103 | $0.138 | $0.147 | $0.1016 | 31,853,412 | 02-28-2023 |
$0.0964 | $0.1325 | $0.0964 | $0.135 | $0.092 | 36,702,688 | 02-27-2023 |
$0.083 | $0.129 | $0.083 | $0.1291 | $0.08 | 21,176,315 | 02-24-2023 |
$0.1686 | $0.185 | $0.1686 | $0.185 | $0.16 | 765,843 | 02-23-2023 |
News, Short Squeeze, Breakout and More Instantly...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that the Regulatory ...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that, concurr...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it will wind-down its operati...